## Lorenzo Leoncini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5964229/publications.pdf

Version: 2024-02-01

66234 95083 6,578 181 42 68 citations h-index g-index papers 193 193 193 5594 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Burkitt lymphoma with a granulomatous reaction: an M1/Th1â€polarised microenvironment is associated with controlled growth and spontaneous regression. Histopathology, 2022, 80, 430-442.	1.6	8
2	Epstein–Barr virus positivity as a defining pathogenetic feature of Burkitt lymphoma subtypes. British Journal of Haematology, 2022, 196, 468-470.	1.2	8
3	A refined approach to the diagnosis of Burkitt lymphoma in a resourceâ€poor setting. Histopathology, 2022, 80, 743-745.	1.6	4
4	The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia, 2022, 36, 1720-1748.	3.3	1,023
5	MiR-200c-3p Contrasts PD-L1 Induction by Combinatorial Therapies and Slows Proliferation of Epithelial Ovarian Cancer through Downregulation of Î <sup>2</sup> -Catenin and c-Myc. Cells, 2021, 10, 519.	1.8	20
6	Distinct pattern of lymphoid neoplasms characterizations according to the WHO classification (2016) and prevalence of associated Epstein–Barr virus infection in Nigeria population. Infectious Agents and Cancer, 2021, 16, 36.	1.2	2
7	MicroRNA and Other Non-Coding RNAs in Epstein–Barr Virus-Associated Cancers. Cancers, 2021, 13, 3909.	1.7	15
8	Epstein–Barr virus reactivation influences clonal evolution in human herpesvirusâ€8â€related lymphoproliferative disorders. Histopathology, 2021, 79, 1099-1107.	1.6	2
9	Metabolic Switch and Cytotoxic Effect of Metformin on Burkitt Lymphoma. Frontiers in Oncology, 2021, 11, 661102.	1.3	3
10	First-Line Pharmacotherapies and Survival among Patients Diagnosed with Non-Resectable NSCLC: A Real-Life Setting Study with Gender Prospective. Cancers, 2021, 13, 6129.	1.7	11
11	IGHV mutational status of nodal marginal zone lymphoma by NGS reveals distinct pathogenic pathways with different prognostic implications. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 143-150.	1.4	5
12	Follicular lymphoma t $(14;18)$ -negative is genetically a heterogeneous disease. Blood Advances, 2020, 4, 5652-5665.	2.5	67
13	A 70% cut-off for MYC protein expression in diffuse large B cell lymphoma identifies a high-risk group of patients. Haematologica, 2020, 105, 2667-2670.	1.7	20
14	Immune landscape in Burkitt lymphoma reveals M2-macrophage polarization and correlation between PD-L1 expression and non-canonical EBV latency program. Infectious Agents and Cancer, 2020, 15, 28.	1.2	30
15	Frequent traces of EBV infection in Hodgkin and non-Hodgkin lymphomas classified as EBV-negative by routine methods: expanding the landscape of EBV-related lymphomas. Modern Pathology, 2020, 33, 2407-2421.	2.9	44
16	Burkitt Lymphoma. Encyclopedia of Pathology, 2020, , 87-98.	0.0	0
17	Prognostic impact of tumor-associated macrophages, lymphocyte-to-monocyte and neutrophil-to-lymphocyte ratio in diffuse large B-cell lymphoma. American Journal of Blood Research, 2020, 10, 97-108.	0.6	3
18	MYC protein expression scoring and its impact on the prognosis of aggressive B-cell lymphoma patients. Haematologica, 2019, 104, e25-e28.	1.7	32

#	Article	IF	Citations
19	Interplay between the Epigenetic Enzyme Lysine (K)-Specific Demethylase 2B and Epstein-Barr Virus Infection. Journal of Virology, 2019, 93, .	1.5	17
20	p66Shc deficiency in the $E\hat{1}\frac{1}{4}$ -TCL1 mouse model of chronic lymphocytic leukemia enhances leukemogenesis by altering the chemokine receptor landscape. Haematologica, 2019, 104, 2040-2052.	1.7	17
21	Role of Epstein-Barr virus in transformation of follicular lymphoma to diffuse large B-cell lymphoma: a case report and review of the literature. Haematologica, 2019, 104, e269-e273.	1.7	13
22	<i>IGHV1</i> status in chronic lymphocytic leukemia identify ethnic groups with an aggressive clinical course <i>(Comment to Giudice ID, Foà R. Haematologica. 2019;104(2):219-221)</i> Haematologica, 2019, 104, e493-e493.	1.7	0
23	Molecular switch from MYC to MYCN expression in MYC protein negative Burkitt lymphoma cases. Blood Cancer Journal, 2019, 9, 91.	2.8	21
24	The mutational landscape of Burkitt-like lymphoma with 11q aberration is distinct from that of Burkitt lymphoma. Blood, 2019, 133, 962-966.	0.6	69
25	Pathology and Molecular Pathogenesis of Burkitt Lymphoma and Lymphoblastic Lymphoma. Technik Im Fokus, 2019, , 75-94.	0.2	1
26	How inâ€depth histological look may allow challenging diagnosis: The case of a primary in situ mantle cell neoplasm of the appendix. Hematological Oncology, 2018, 36, 376-378.	0.8	2
27	Granulysin, a novel marker for extranodal NK/T cell lymphoma, nasal type. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 473, 749-757.	1.4	6
28	Epstein–Barr Virus-Induced Metabolic Rearrangements in Human B-Cell Lymphomas. Frontiers in Microbiology, 2018, 9, 1233.	1.5	30
29	Pathobiologic Roles of Epstein–Barr Virus-Encoded MicroRNAs in Human Lymphomas. International Journal of Molecular Sciences, 2018, 19, 1168.	1.8	36
30	Burkitt Lymphoma. Encyclopedia of Pathology, 2018, , 1-12.	0.0	0
31	Evaluation of the prognostic role of tumourâ€associated macrophages in newly diagnosed classical Hodgkin lymphoma and correlation with early FDGâ€PET assessment. Hematological Oncology, 2017, 35, 69-78.	0.8	25
32	The surgical pathology laboratory in Mwanza, Tanzania: a survey on the reproducibility of diagnoses after the first years of autonomous activity. Infectious Agents and Cancer, 2017, 12, 6.	1.2	5
33	Preferential Usage of Specific Immunoglobulin Heavy Chain Variable Region Genes With Unmutated Profile and Advanced Stage at Presentation Are Common Features in Patients With Chronic Lymphocytic Leukemia From Senegal. American Journal of Clinical Pathology, 2017, 148, 545-554.	0.4	6
34	Unveiling Another Missing Piece in EBV-Driven Lymphomagenesis: EBV-Encoded MicroRNAs Expression in EBER-Negative Burkitt Lymphoma Cases. Frontiers in Microbiology, 2017, 8, 229.	1.5	35
35	MicroRNAs sequencing unveils distinct molecular subgroups of plasmablastic lymphoma. Oncotarget, 2017, 8, 107356-107373.	0.8	24
36	Building Thermal Exergy Analysis., 2017,, 541-551.		0

#	Article	IF	CITATIONS
37	The cell of origin of Burkitt lymphoma: germinal centre or not germinal centre?. Histopathology, 2016, 69, 885-886.	1.6	9
38	Optimal Minimal Panels of Immunohistochemistry for Diagnosis of B-Cell Lymphoma for Application in Countries With Limited Resources and for Triaging Cases Before Referral to Specialist Centers. American Journal of Clinical Pathology, 2016, 145, 687-695.	0.4	11
39	Clonality Analysis of Immunoglobulin Gene Rearrangement by Next-Generation Sequencing in Endemic Burkitt Lymphoma Suggests Antigen Drive Activation of BCR as Opposed to Sporadic Burkitt Lymphoma. American Journal of Clinical Pathology, 2016, 145, 116-127.	0.4	35
40	Virus-encoded microRNA contributes to the molecular profile of EBV-positive Burkitt lymphomas. Oncotarget, 2016, 7, 224-240.	0.8	33
41	The tumor virus landscape of AIDS-related lymphomas. Blood, 2015, 125, e14-e22.	0.6	67
42	Burkitt lymphoma beyond MYC translocation: N-MYC and DNA methyltransferases dysregulation. BMC Cancer, 2015, 15, 668.	1.1	26
43	A review of the pattern of AIDS defining, HIV associated neoplasms and premalignant lesions diagnosed from 2000–2011 at Kenyatta National Hospital, Kenya. Infectious Agents and Cancer, 2015, 10, 28.	1.2	18
44	The presence of Epstein-Barr virus significantly impacts the transcriptional profile in immunodeficiency-associated Burkitt lymphoma. Frontiers in Microbiology, 2015, 6, 556.	1.5	25
45	Distinct Viral and Mutational Spectrum of Endemic Burkitt Lymphoma. PLoS Pathogens, 2015, 11, e1005158.	2.1	127
46	Effect of Reference State Characteristics on the Thermal Exergy Analysis of a Building. Energy Procedia, 2015, 83, 177-186.	1.8	10
47	A Look Into the Evolution of Epstein-Barr Virus–Induced Lymphoproliferative Disorders: A Case Study. American Journal of Clinical Pathology, 2015, 144, 817-822.	0.4	17
48	Langerhans cell sarcoma following marginal zone lymphoma: expanding the knowledge on mature B cell plasticity. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 467, 471-480.	1.4	26
49	Thermal Exergy Analysis of a Building. Energy Procedia, 2014, 62, 723-732.	1.8	13
50	Molecular signature of Epstein Barr virus-positive Burkitt lymphoma and post-transplant lymphoproliferative disorder suggest different roles for Epstein Barr virus. Frontiers in Microbiology, 2014, 5, 728.	1.5	37
51	HIV-1 Tat induces DNMT over-expression through microRNA dysregulation in HIV-related non Hodgkin lymphomas. Infectious Agents and Cancer, 2014, 9, 41.	1.2	24
52	The Epstein Barr-encoded BART-6-3p microRNA affects regulation of cell growth and immuno response in Burkitt lymphoma. Infectious Agents and Cancer, $2014$ , $9$ , $12$ .	1.2	55
53	Correlation of EGFR, pEGFR and p16INK4 expressions and high risk HPV infection in HIV/AIDS-related squamous cell carcinoma of conjunctiva. Infectious Agents and Cancer, 2014, 9, 7.	1.2	8
54	Plasmablastic transformation of a pre-existing plasmacytoma: a possible role for reactivation of Epstein Barr virus infection. Haematologica, 2014, 99, e235-e237.	1.7	22

#	Article	IF	Citations
55	Abstract 5173: Identification of single-nucleotide variants by high-throughput RNA sequencing in endemic Burkitt Lymphoma. , $2014,  ,  .$		1
56	Definition of Burkitt Lymphoma. , 2013, , 81-93.		1
57	Lymphoepithelial-like carcinoma of the parotid gland: a case report and a brief review of the western literature. Diagnostic Pathology, 2013, 8, 115.	0.9	32
58	Diagnostic Accuracy of the Primary Care Screener for Affective Disorder (PC-SAD) in Primary Care. Clinical Practice and Epidemiology in Mental Health, 2013, 9, 164-170.	0.6	5
59	Epstein-Barr nuclear antigen 1 induces expression of the cellular microRNA hsa-miR-127 and impairing B-cell differentiation in EBV-infected memory B cells. New insights into the pathogenesis of Burkitt lymphoma. Blood Cancer Journal, 2012, 2, e84-e84.	2.8	46
60	EBV Reactivation and Chromosomal Polysomies: <i>Euphorbia tirucalli </i> as a Possible Cofactor in Endemic Burkitt Lymphoma. Advances in Hematology, 2012, 2012, 1-11.	0.6	14
61	Aggressive B-Cell Lymphomas. Advances in Hematology, 2012, 2012, 1-1.	0.6	1
62	Treatment of Burkitt lymphoma in equatorial Africa using a simple threeâ€drug combination followed by a salvage regimen for patients with persistent or recurrent disease. British Journal of Haematology, 2012, 158, 749-762.	1.2	44
63	Targeted genomic sequencing of pediatric Burkitt lymphoma identifies recurrent alterations in antiapoptotic and chromatin-remodeling genes. Blood, 2012, 120, 5181-5184.	0.6	96
64	The Alteration of Lipid Metabolism in Burkitt Lymphoma Identifies a Novel Marker: Adipophilin. PLoS ONE, 2012, 7, e44315.	1.1	62
65	Inhibition of miR-9 de-represses HuR and DICER1 and impairs Hodgkin lymphoma tumour outgrowth in vivo. Oncogene, 2012, 31, 5081-5089.	2.6	85
66	Patients with thymomas have an increased risk of developing additional malignancies: lack of immunological surveillance?. Histopathology, 2012, 60, 437-442.	1.6	8
67	Human peripheral blood lymphocytes and fibroblasts as Notch3 expression models. Journal of Cellular Physiology, 2012, 227, 1771-1775.	2.0	5
68	Novel Genomic Alterations in MCL1 and ARID1A Identified in Pediatric Burkitt Lymphoma Using Targeted High-Throughput Sequencing. Blood, 2012, 120, 899-899.	0.6	0
69	The different epidemiologic subtypes of Burkitt lymphoma share a homogenous micro RNA profile distinct from diffuse large B-cell lymphoma. Leukemia, 2011, 25, 1869-1876.	3.3	110
70	Infectious agents and lymphoma. Seminars in Diagnostic Pathology, 2011, 28, 178-187.	1.0	6
71	Gene expression analysis uncovers similarity and differences among Burkitt lymphoma subtypes. Blood, 2011, 117, 3596-3608.	0.6	128
72	A20 (TNFAIP3) genetic alterations in EBV-associated AIDS-related lymphoma. Blood, 2011, 117, 4852-4854.	0.6	28

#	Article	IF	CITATIONS
73	Diagnosis of Burkitt lymphoma using an algorithmic approach – applicable in both resourceâ€poor and resourceâ€rich countries. British Journal of Haematology, 2011, 154, 770-776.	1.2	55
74	Lymphomas in subâ€Saharan Africa – what can we learn and how can we help in improving diagnosis, managing patients and fostering translational research?. British Journal of Haematology, 2011, 154, 696-703.	1.2	78
75	A review of the trends of lymphomas in the equatorial belt of Africa. Hematological Oncology, 2011, 29, 111-115.	0.8	7
76	Analysis of the IgVH genes in T cell-mediated and antibody-mediated rejection of the kidney graft. Journal of Clinical Pathology, 2011, 64, 47-53.	1.0	3
77	Geographic variation and environmental conditions as cofactors in <i>Chlamydia psittaci</i> association with ocular adnexal lymphomas: a comparison between Italian and African samples. Hematological Oncology, 2010, 28, 20-26.	0.8	34
78	Bâ€cell differentiation in EBVâ€positive Burkitt lymphoma is impaired at posttranscriptional level by miRNAâ€altered expression. International Journal of Cancer, 2010, 126, 1316-1326.	2.3	62
79	Interplay between HIV and microRNAs in AIDS-related lymphomas. Retrovirology, 2010, 7, .	0.9	0
80	Alteration of MicroRNAs Regulated by c-Myc in Burkitt Lymphoma. PLoS ONE, 2010, 5, e12960.	1.1	66
81	Double-staining chromogenic in situ hybridization as a useful alternative to split-signal fluorescence in situ hybridization in lymphoma diagnostics. Haematologica, 2010, 95, 247-252.	1.7	17
82	TNFAIP3 (A20) Genetic Alterations In EBV Associated AIDS Related Lymphomas. Blood, 2010, 116, 802-802.	0.6	0
83	Gene Expression Analysis Uncovers Similarity and Differences Among Burkitt Lymphoma Subtypes. Blood, 2010, 116, 2494-2494.	0.6	2
84	Role of EBV in microRNA dysregulation in Burkitt lymphoma. Seminars in Cancer Biology, 2009, 19, 401-406.	4.3	45
85	Rare lymphoid neoplasms coexpressing B- and T-cell antigens. The role of PAX-5 gene methylation in their pathogenesis. Human Pathology, 2009, 40, 1252-1261.	1.1	27
86	Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior. Blood, 2009, 114, 4696-4702.	0.6	114
87	HIV-1 Tat mimetic of VEGF correlates with increased microvessels density in AIDS-related diffuse large B-cell and Burkitt lymphomas. Journal of Hematopathology, 2008, 1, 3-10.	0.2	12
88	Translocation detection in lymphoma diagnosis by split-signal FISH: a standardised approach. Journal of Hematopathology, 2008, 1, 119-126.	0.2	28
89	<i>MYC</i> translocationâ€negative classical Burkitt lymphoma cases: an alternative pathogenetic mechanism involving miRNA deregulation. Journal of Pathology, 2008, 216, 440-450.	2.1	182
90	Cdk9/Cyclin T1 complex: A key player during the activation/differentiation process of normal lymphoid B cells. Journal of Cellular Physiology, 2008, 215, 276-282.	2.0	20

#	Article	IF	CITATIONS
91	CD34+ Cord Blood Cell-Transplanted Rag2â^'/â^' γcâ^'/â^' Mice as a Model for Epstein-Barr Virus Infection. American Journal of Pathology, 2008, 173, 1369-1378.	1.9	52
92	Selective influences in the expressed immunoglobulin heavy and light chain gene repertoire in hairy cell leukemia. Haematologica, 2008, 93, 697-705.	1.7	32
93	Secretory endometrium highly expresses urocortin messenger RNA and peptide: possible role in the decidualization process. Human Reproduction, 2007, 22, 92-96.	0.4	31
94	High Incidence of Familial Gastric Cancer in Tuscany, a Region in Italy. Oncology, 2007, 72, 243-247.	0.9	25
95	Gene-expression analysis identifies novel RBL2/p130 target genes in endemic Burkitt lymphoma cell lines and primary tumors. Blood, 2007, $110$ , $1301-1307$ .	0.6	37
96	Hereditary diffuse gastric cancer and E-cadherin: Description of the first germline mutation in an Italian family. European Journal of Surgical Oncology, 2007, 33, 448-451.	0.5	41
97	VEGF-D is expressed in activated lymphoid cells and in tumors of hematopoietic and lymphoid tissues. Leukemia and Lymphoma, 2007, 48, 2014-2021.	0.6	15
98	The role of the Cdk9/Cyclin T1 complex in T cell differentiation. Journal of Cellular Physiology, 2007, 212, 411-415.	2.0	25
99	Placental Neurokinin B mRNA Expression Increases at Preterm Labor. Placenta, 2007, 28, 1020-1023.	0.7	11
100	Silencing Human Rb2/p130 with shRNA. Analytical Cellular Pathology, 2007, 29, 265-268.	0.7	0
101	Activity of Rituximab Monotherapy in Refractory Splenic Marginal Zone Lymphoma Complicated with Autoimmune Hemolytic Anemia. Clinical Lymphoma and Myeloma, 2006, 6, 496-499.	1.4	23
102	Subcutaneous Panniculitis Lymphoma: Erythema Nodosum–Like. Clinical Lymphoma and Myeloma, 2006, 7, 239-241.	1.4	5
103	Kaposi's sarcoma–associated herpesvirus/human herpesvirus 8 infection in reactive lymphoid tissues: a model for KSHV/HHV-8–related lymphomas?. Human Pathology, 2006, 37, 23-31.	1.1	21
104	High maternal and fetal plasma urocortin levels in pregnancies complicated by hypertension. Journal of Hypertension, 2006, 24, 1831-1840.	0.3	21
105	IRTA1+ monocytoid B cells in reactive lymphadenitis show a unique topographic distribution and immunophenotype and a peculiar usage and mutational pattern of gVH genes. Journal of Pathology, 2006, 209, 56-66.	2.1	26
106	Update on extranodal lymphomas. Conclusions of the Workshop held by the EAHP and the SH in Thessaloniki, Greece. Histopathology, 2006, 48, 481-504.	1.6	77
107	Retinoblastoma gene family expression in lymphoid tissues. Oncogene, 2006, 25, 5309-5314.	2.6	12
108	Overlapping morphologic and immunophenotypic profiles in small B-cell lymphoma. A report of two cases. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2006, 449, 320-327.	1.4	10

#	Article	IF	CITATIONS
109	pRb2/p130 and VEGF expression in endometrial carcinoma in relation to angiogenesis and histopathologic tumor grade. Cancer Biology and Therapy, 2006, 5, 84-88.	1.5	28
110	The effects of HIV-1 Tat protein on cell cycle during cervical carcinogenesis. Cancer Biology and Therapy, 2006, 5, 684-690.	1.5	60
111	Urocortin expression is downregulated in human endometrial carcinoma. Journal of Endocrinology, 2006, 190, 99-105.	1.2	30
112	Routine assessment of hormonal receptor and her-2/neu status underscores the need for more therapeutic targets in Kenyan women with breast cancer. , 2006, 28, 97-103.		13
113	Immunoglobulin gene analysis reveals 2 distinct cells of origin for EBV-positive and EBV-negative Burkitt lymphomas. Blood, 2005, 106, 1031-1036.	0.6	153
114	Aggressive B-cell lymphomas: a review based on the workshop of the XI Meeting of the European Association for Haematopathology. Histopathology, 2005, 46, 241-255.	1.6	29
115	The NFATc1 transcription factor is widely expressed in white cells and translocates from the cytoplasm to the nucleus in a subset of human lymphomas. British Journal of Haematology, 2005, 128, 333-342.	1.2	69
116	Expression of Cell Cycle–Regulated Proteins pRB2/p130, p107, E2F4, p27, and pCNA in Salivary Gland Tumors: Prognostic and Diagnostic Implications. Clinical Cancer Research, 2005, 11, 3265-3273.	3.2	36
117	Cdk9 regulates neural differentiation and its expression correlates with the differentiation grade of neuroblastoma and PNET tumors. Cancer Biology and Therapy, 2005, 4, 277-281.	1.5	51
118	Lacunar and Reed-Sternberg–Like Cells in Follicular Lymphomas Are Clonally Related to the Centrocytic and Centroblastic Cells as Demonstrated by Laser Capture Microdissection. American Journal of Clinical Pathology, 2004, 122, 858-864.	0.4	21
119	CDK9/CYCLIN T1 expression during normal lymphoid differentiation and malignant transformation. Journal of Pathology, 2004, 203, 946-952.	2.1	54
120	Lacunar and reed-sternberg-like cells in follicular lymphomas are clonally related to the centrocytic and centroblastic cells as demonstrated by laser capture microdissection. American Journal of Clinical Pathology, 2004, 122, 858-64.	0.4	6
121	Cytokeratin-positive interstitial cell neoplasm: a case report and classification issues. Histopathology, 2003, 43, 491-494.	1.6	29
122	Typical genomic imbalances in primary MALT lymphoma of the orbit. Journal of Pathology, 2003, 200, 656-660.	2.1	33
123	Interaction between HIV-1 Tat and pRb2/p130: a possible mechanism in the pathogenesis of AIDS-related neoplasms. Oncogene, 2003, 22, 6214-6219.	2.6	50
124	Pathologic aspects of AIDS malignancies. Oncogene, 2003, 22, 6639-6645.	2.6	45
125	Burkitt's lymphoma: new insights into molecular pathogenesis. Journal of Clinical Pathology, 2003, 56, 188-192.	1.0	79
126	Cell kinetics and cell cycle regulation in lymphomas. Journal of Clinical Pathology, 2002, 55, 648-655.	1.0	10

#	Article	IF	CITATIONS
127	Immunoglobulin Gene Rearrangement Analysis in Composite Hodgkin Disease and Large B-Cell Lymphoma: Evidence for Receptor Revision of Immunoglobulin Heavy Chain Variable Region Genes in Hodgkin-Reed-Sternberg Cells?. Diagnostic Molecular Pathology, 2002, 11, 2-8.	2.1	46
128	Expression of RB2/p130 tumor-suppressor gene in AIDS-related non-Hodgkin's lymphomas: Implications for disease pathogenesis. Human Pathology, 2002, 33, 723-731.	1.1	45
129	Diffuse large B-cell lymphoma: one or more entities? Present controversies and possible tools for its subclassification. Histopathology, 2002, 41, 482-509.	1.6	<b>7</b> 5
130	Cdk9, a member of the cdc2-like family of kinases, binds to gp130, the receptor of the IL-6 family of cytokines. Oncogene, 2002, 21, 7464-7470.	2.6	26
131	Hodgkin's lymphoma: the pathologist's viewpoint. Journal of Clinical Pathology, 2002, 55, 162-176.	1.0	189
132	p53 mutation in breast cancer. Correlation with cell kinetics and cell of origin. Journal of Clinical Pathology, 2002, 55, 461-466.	1.0	33
133	Missing expression of pRb2/p130 in human retinoblastomas is associated with reduced apoptosis and lesser differentiation. Investigative Ophthalmology and Visual Science, 2002, 43, 3602-8.	3.3	25
134	Detection of tyrosinase mRNA in tumor tissue microdissections from classic Kaposi's sarcoma. Annals of Oncology, 2001, 12, 1765-1766.	0.6	0
135	Performance of cytology and colposcopy in diagnosis of cervical intraepithelial neoplasia (CIN) in HIV-positive and HIV-negative women. Cytopathology, 2001, 12, 84-93.	0.4	21
136	Expression of the ALK protein by anaplastic large-cell lymphomas correlates with high proliferative activity., 2000, 86, 777-781.		10
137	Genetic Alterations of the Retinoblastoma-Related Gene RB2/p130 Identify Different Pathogenetic Mechanisms in and among Burkitt's Lymphoma Subtypes. American Journal of Pathology, 2000, 156, 751-760.	1.9	70
138	Cellular kinetics and expression of bcl-2 and p53 in ductal carcinoma of the breast Oncology Reports, 2000, 7, 473-8.	1.2	7
139	Pathological Case of the Month. JAMA Pediatrics, 1999, 153, 1199.	3.6	9
140	Expression of p34cdc2 and cyclins A and B compared to other proliferative features of non-Hodgkin's lymphomas: A multivariate cluster analysis., 1999, 83, 203-209.		14
141	Cellular kinetic differences between Hodgkin's and anaplastic large cell lymphomas: Relation to the expression of p34cdc2 and cyclin B-1., 1998, 77, 408-414.		12
142	HIV-associated malignant lymphomas in Kenya (Equatorial Africa). Human Pathology, 1998, 29, 1285-1289.	1.1	55
143	Fatal Cytomegalovirus Infection in a Patient without Evidence of Prior Immunodeficiency. Clinical Infectious Diseases, 1998, 27, 659-660.	2.9	1
144	Immunohistochemistry of Bone-Marrow Biopsy. Leukemia and Lymphoma, 1997, 26, 69-75.	0.6	11

#	Article	IF	CITATIONS
145	Mitotic Activity and Nuclear DNA Damage of Large Cells in Hodgkin's Disease: Comparison with the Expression of p53 and bcl-2 Proteins and the Presence of Epstein-Barr Virus. Leukemia and Lymphoma, 1997, 25, 153-161.	0.6	6
146	Chronic progressive leptomeningitis associated with measles virus. Lancet, The, 1997, 350, 338-339.	6.3	11
147	Peripheral T-cell lymphomas. Clinico-pathologic study of 168 cases diagnosed according to the R.E.A.L. Classification. Annals of Oncology, 1997, 8, 583-592.	0.6	124
148	Cell Kinetics, Morphology, and MolecularlgVHGene Rearrangements in Hodgkin's Disease. Leukemia and Lymphoma, 1997, 26, 307-316.	0.6	11
149	Pyothorax-associated lymphoma: Description of the first two cases detected in Italy. Annals of Oncology, 1997, 8, 1133-1138.	0.6	38
150	CELLULAR KINETIC AND PHENOTYPIC HETEROGENEITY IN AND AMONG BURKITT'S AND BURKITT-LIKE LYMPHOMAS. , $1997$ , $182$ , $145$ - $150$ .		33
151	Antigen retrieval techniques in immunohistochemistry: comparison of different methods. , 1997, 183, 116-123.		244
152	Growth patterns of diffuse non-Hodgkin's lymphomas estimated from mitotic and apoptotic indices. , $1997, 73, 178-183.$		5
153	Molecular Findings and Classification of Malignant Lymphomas. Acta Haematologica, 1996, 95, 181-187.	0.7	6
154	Neoplastic cells of Hodgkin's disease show differences in EBV expression between Kenya and Italy. , 1996, 65, 781-784.		57
155	Growthvs. DNA strand breaks in Hodgkin's disease: Impaired proliferative ability of Hodgkin and Reed-Sternberg cells. , 1996, 66, 179-183.		22
156	Stage-related differences of mitotic and apoptotic indices, and bcl-2 protein expression in diffusely growing non-Hodgkin's lymphomas., 1996, 68, 436-440.		6
157	Low incidence of Epstein-Barr virus presence in primary cutaneous T-cell lymphoproliferations. British Journal of Dermatology, 1996, 134, 276-281.	1.4	47
158	Abortive Mitoses and Nuclear DNA Fragmentation in CD30+ Large Cells of Hodgkin's Disease. Leukemia and Lymphoma, 1996, 22, 119-124.	0.6	20
159	Molecular Findings and Classification of Malignant Lymphomas. , 1996, , 135-144.		0
160	Revised European-American Lymphoma Classification. Current Opinion in Oncology, 1995, 7, 401-407.	1,1	19
161	Presence of the bcl-2 protein and apoptosis in non-hodgkin lymphomas with diffuse growth pattern. International Journal of Cancer, 1995, 61, 826-831.	2.3	28
162	Low versus high cell turnover in diffusely growing non-Hodgkin's lymphomas. Journal of Pathology, 1995, 177, 335-341.	2.1	35

#	Article	IF	CITATIONS
163	Spatial distribution of mitosis, apoptosis and small blood vessels in malignant diffuse follicular-center-cell lymphomas: A nearest-neighbor analysis. International Journal of Cancer, 1994, 59, 313-318.	2.3	5
164	Comparison between the monoclonal antibodies Ki-67 and PC 10 in 125 malignant lymphomas. Journal of Pathology, 1993, 169, 397-403.	2.1	48
165	Apoptotic Index: Discriminant Feature for the Differentiation of Cutaneous Diffuse Malignant Follicular Center Cell Lymphomas from Lymphoid Hyperplasia. Journal of Investigative Dermatology, 1993, 100, 699-704.	0.3	20
166	IDENTIFICATION OF MONOCLONAL B-CELL POPULATIONS IN LYMPHOID INFILTRATES OF LACRIMAL GLAND BY RAPID CYCLE POLYMERASE CHAIN-REACTION. International Journal of Oncology, 1993, 3, 897-900.	1.4	1
167	Distinction Between Diffuse Cutaneous Malignant Follicular Center Cell Lymphoma and Lymphoid Hyperplasia by Computerized Nuclear Image Analysis. American Journal of Dermatopathology, 1993, 15, 415-422.	0.3	5
168	Epsteinâ€barr virus and gastric cancer: Data and unanswered questions. International Journal of Cancer, 1993, 53, 898-901.	2.3	58
169	Phenotypic overlaps between pleomorphic malignant T-cell lymphomas and mixed-cellularity Hodgkin's disease. International Journal of Cancer, 1992, 52, 202-207.	2.3	7
170	Diffuse centrocytic and/or centroblastic malignant non-hodgkin's lymphomas: Comparison of mitotic and pyknotic (apoptotic) indices. International Journal of Cancer, 1991, 47, 38-43.	2.3	55
171	Unresectable retroperitoneal malignant fibrous histiocytoma: Prolonged complete remission following chemoradiotherapy. Journal of Surgical Oncology, 1988, 38, 160-164.	0.8	9
172	Distribution of cytoskeletal and contractile proteins in normal and tumour bearing salivary and lacrimal glands. Virchows Archiv A, Pathological Anatomy and Histopathology, 1988, 412, 329-337.	1.4	57
173	Flow cytometric analysis of DNA ploidy pattern from deparaffinized formalinâ€fixed gastric cancer tissue. International Journal of Cancer, 1988, 42, 868-871.	2.3	23
174	Mantle zone lymphoma: A morphometric comparison with centrocytic and immunocytic lymphomas and reactive secondary follicles. Human Pathology, 1988, 19, 1293-1300.	1.1	8
175	Immune response against P815X2 mastocytoma growing in syngeneic DBA/2 mice I. Morphometric assessment of lymph node immunoreactivity and analysis of circulating antibodies. Experimental Pathology, 1986, 30, 65-74.	0.5	1
176	Immune response against P815X2 mastocytoma growing in syngeneic DBA/2 mice II. Morphometric assessment of immunoreactivity in the thymus and spleen related to lymphocyte subsets in peripheral blood. Experimental Pathology, 1986, 30, 75-82.	0.5	0
177	Morphometry of Lymphoid Organs in Health and Disease. Pathology Research and Practice, 1984, 179, 207-209.	1.0	3
178	Orbital lymphoid neoplasms: Immunohistochemical patterns correlated with histopathological and clinical aspects. Orbit, 1984, 3, 97-110.	0.5	3
179	A morphometric semiautomated method for analyzing cell nuclei in lymph node sections from non-Hodgkin's lymphomas. — Significance of data. Experimental Pathology, 1983, 24, 237-241.	0.5	13
180	Bronchogenic adenocarcinoma and Hodgkin $\hat{E}$ 4s disease diagnosed in the same lung simultaneously. American Journal of Surgical Pathology, 1982, 6, 277-279.	2.1	0

#	Article	IF	CITATIONS
181	Bronchogenic carcinoma: Survival after surgical treatment according to stage, histologic type and immunomorphologic changes in regional lymph nodes. Cancer, 1981, 48, 2288-2295.	2.0	26